Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX030 Pharmacokinetics Study in MDS
NCT04608110Phase 1Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cedazuridine + azacitidine in myelodysplastic syndrome (MDS) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Area Under the Curve ratio of AZA at 1 month. Started Oct 2020; status: recruiting.
02
Drugs
cedazuridine + azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04608110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608110.